☆ 4.7 Article

Progress in the Discovery and Development of Heat Shock Protein 90 (Hsp90) Inhibitors

JOURNAL OF MEDICINAL CHEMISTRY (2014)

期刊

JOURNAL OF MEDICINAL CHEMISTRY

卷 57, 期 21, 页码 8718-8728

出版社

AMER CHEMICAL SOC

DOI: 10.1021/jm500823a

关键词

-

类别

Chemistry, Medicinal

向作者/读者索取更多资源

Protocol

Reagent

摘要

The discovery and clinical development of heat shock protein 90 (Hsp90) inhibitors continue to progress. A number of Hsp90 inhibitors are in clinical trials, and preclinical discoveries of new chemotypes that bind to distinct regions in the protein as well as isoform selective compounds are active areas of research. This review will highlight progress in the field since 2010.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Cell Biology

Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy

Xiude Ren, Tao Li, Wei Zhang, Xuejun Yang

Summary: Heat-shock protein 90 (HSP90) is an important molecule chaperone associated with tumorigenesis and malignancy. It plays a role in the malignant behaviors of cancer cells, but currently there are no effective single-agent treatments. Combining HSP90 inhibitors with other anticancer therapies may be a better strategy.

CELLS (2022)

添加到收藏夹

Review Cell Biology

The Distinct Assignments for Hsp90α and Hsp90β: More Than Skin Deep

Cheng Chang, Xin Tang, David T. Woodley, Mei Chen, Wei Li

Summary: For a long time, the cytosolic Hsp90 alpha and Hsp90 beta proteins have been considered evolutionarily conserved, ATP-driven chaperones that play a crucial role in basic research and clinical trials. Recent studies have challenged this notion and highlighted the failures of paradigm-based clinical trials. It is now known that Hsp90 alpha and Hsp90 beta are ubiquitously expressed in all cell types but have distinct and irreplaceable functions. Understanding the differences between Hsp90 alpha and Hsp90 beta could lead to new therapeutic approaches for human disorders such as cancer.

CELLS (2023)

添加到收藏夹

Article Chemistry, Multidisciplinary

Development of the first geldanamycin-based HSP90 degraders

Silas Wurnig, Melina Vogt, Julian Hogenkamp, Niklas Dienstbier, Arndt Borkhardt, Sanil Bhatia, Finn K. Hansen

Summary: Despite limitations with HSP90 inhibitors as anticancer drugs, a new approach using PROTACs to degrade the protein shows promise. This study focuses on designing and evaluating geldanamycin-based HSP90 degraders based on the PROTAC technology. The best degrader, 3a, effectively reduced HSP90 alpha and HSP90 beta levels in cells using the ubiquitin-proteasome pathway.

FRONTIERS IN CHEMISTRY (2023)

添加到收藏夹

Article Oncology

Combined BRAF, MEK, and heat-shock protein 90 (HSP90) inhibition in advanced BRAF V600-mutant melanoma

Zeynep Eroglu, Y. Ann Chen, Inna Smalley, Jiannong Li, Joseph K. Markowitz, Andrew S. Brohl, Leticia Tetteh, Hayley Taylor, Vernon K. Sondak, Nikhil I. Khushalani, Keiran S. M. Smalley

Summary: In this study, the efficacy and safety of vemurafenib and cobimetinib in combination with different doses of the HSP90 inhibitor XL888 for the treatment of advanced melanoma were explored. The study found that this combination therapy showed activity in some patients, but also had significant toxicity.

CANCER (2023)

添加到收藏夹

Article Chemistry, Medicinal

The Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with pan-Hsp90 Inhibition

Sanket J. Mishra, Weiya Liu, Kristin Beebe, Monimoy Banerjee, Caitlin N. Kent, Vitumbiko Munthali, John Koren, John A. Taylor, Leonard M. Neckers, Jeffrey Holzbeierlein, Brian S. J. Blagg

Summary: Hsp90 proteins play a crucial role in cancer progression, and inhibiting their activity may be beneficial for cancer treatment. Current Hsp90 inhibitors target all isoforms, potentially leading to adverse effects. Utilizing Hsp90 beta-selective inhibitors as a new approach for cancer therapy holds promise in reducing side effects.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Functional and Stress Response Analysis of Heat Shock Proteins 40 and 90 of Giant River Prawn (Macrobrachium rosenbergii) under Temperature and Pathogenic Bacterial Exposure Stimuli

Tanya Ju-Ngam, Nichanun McMillan, Mamoru Yoshimizu, Hisae Kasai, Ratree Wongpanya, Prapansak Srisapoome

Summary: This research conducted molecular characterization and biofunctional analyses of Hsp40 and Hsp90 genes in giant river prawns under various stress conditions. The highest similarity scores of these genes were found with crustaceans. Expression patterns of Mr-hsp40 and Mr-hsp90 were different under Aeromonas hydrophila challenge and heat-cold shock conditions, highlighting their significant roles in stress responses.

BIOMOLECULES (2021)

添加到收藏夹

Article Cell Biology

The Heat Shock Protein 90 Inhibitor, AT13387, Protects the Alveolo-Capillary Barrier and Prevents HCl-Induced Chronic Lung Injury and Pulmonary Fibrosis

Ruben M. L. Colunga Biancatelli, Pavel Solopov, Christiana Dimitropoulou, Betsy Gregory, Tierney Day, John D. Catravas

Summary: The HSP90 inhibitor, AT13387, shows promising potential in preventing chronic lung injury induced by HCl and protecting the endothelial barrier. It reduces inflammation and fibrosis caused by HCl exposure and restores lung function.

CELLS (2022)

添加到收藏夹

Review Cell Biology

Inhibitors of the Plasmodium falciparum Hsp90 towards Selective Antimalarial Drug Design: The Past, Present and Future

Melissa Louise Stofberg, Celine Caillet, Marianne de Villiers, Tawanda Zininga

Summary: Malaria remains a major killer parasitic disease in tropical settings, with the development of antimalarial drug resistance posing a significant challenge in disease control. Therefore, there is a need to explore new strategies and treatment options to reverse the development of antimalarial drug resistance.

CELLS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Development of Computational Approaches with a Fragment-Based Drug Design Strategy: In Silico Hsp90 Inhibitors Discovery

Roberto Leon, Jorge Soto-Delgado, Elizabeth Montero, Matias Vargas

Summary: The study utilizes a fragment-based drug design strategy and heuristic search algorithm to design new inhibitors by deconstructing known ligands and reassembling fragments to generate new ligands. Evaluation of the approaches involves comparing the binding energy of the new ligands with the known ligands.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Natural HSP90 inhibitors as a potential therapeutic intervention in treating cancers: A comprehensive review

Hui Yi Liew, Xin Yoong Tan, Hong Hao Chan, Kooi Yeong Khaw, Yong Sze Ong

Summary: This review analyzes the chemical and biological activities of natural Hsp90 inhibitors, discusses their efficacy in tumor models, and explores their pharmacodynamics and pharmacokinetics.

PHARMACOLOGICAL RESEARCH (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Heat Shock Protein 90 (Hsp90) and Hsp70 as Potential Therapeutic Targets in Autoimmune Skin Diseases

Stefan Tukaj, Krzysztof Sitko

Summary: Over a hundred different autoimmune diseases have been described to date, affecting various organs including the skin. The loss of immune tolerance in autoimmune diseases leads to chronic inflammation and tissue damage. Current treatments focus on immunosuppression but may cause serious adverse effects. Heat shock proteins Hsp90 and Hsp70 have been identified as potential therapeutic targets for autoimmune skin diseases.

BIOMOLECULES (2022)

添加到收藏夹

Article Veterinary Sciences

Hypoglycemia Impairs the Heat Shock Protein Response: A Risk for Heat Shock in Cattle?

Samuel A. Atkin, Abu Saleh Md Moin, Stephen L. Atkin, Alexandra E. Butler

Summary: This study investigated the effects of hypoglycemia on the heat shock-related protein pathway. The results showed that hypoglycemia significantly decreased the expression of HSP90, 70, 27, and ubiquitin proteins, which are important for the protective response against heat stress.

FRONTIERS IN VETERINARY SCIENCE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

In Silico Discovery and Optimisation of a Novel Structural Class of Hsp90 C-Terminal Domain Inhibitors

Ziva Zajec, Jaka Dernovsek, Martina Gobec, Tihomir Tomasic

Summary: Hsp90 is a promising target for cancer treatment. The discovery of a novel class of Hsp90 CTD inhibitors through virtual screening provides new starting points for further development, showing enhanced antiproliferative activities in breast cancer and sarcoma cell lines.

BIOMOLECULES (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Sayan Dutta Gupta, Dae-Geun Song, SueJung Lee, Jae Wook Lee, Jin-Soo Park, Chrisostomos Prodromou, Cheol-Ho Pan

Summary: Hsp90 is a potential anticancer target due to its chaperoning effect on oncogenic proteins. Its activity relies on the hydrolysis of ATP to ADP and phosphate. Inhibiting the binding of ATP to Hsp90 effectively suppresses its function.

JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2023)

添加到收藏夹

Article Chemistry, Medicinal

Discovery and Development of a Selective Inhibitor of the ER Resident Chaperone Grp78

Andrew J. Ambrose, Jared Sivinski, Christopher J. Zerio, Xiaoyi Zhu, Jack Godek, Vlad K. Kumirov, Teresa Coma Brujas, Joan Torra Garcia, Anandhan Annadurai, Cody J. Schmidlin, Alyssa Werner, Taoda Shi, Reza Beheshti Zavareh, Luke Lairson, Donna D. Zhang, Eli Chapman

Summary: A recent study found that a fluorescence polarization assay can identify substrate-competitive Hsp70 inhibitors with isoform selectivity. In this study, the assay was used in a moderate-throughput screen to discover a druglike amino-acid-based inhibitor that specifically targets the endoplasmic reticular Hsp70, Grp78. The potency and selectivity of the inhibitor were further optimized through structure-activity relationship studies, but it showed little effect on cancer cell lines until it was combined with endoplasmic reticulum stress-inducing agents. The inhibitor demonstrated better potency in a spheroid tumor model compared to two-dimensional models. These findings represent the first reported isoform-selective small-molecule-competitive inhibitors of an Hsp70-substrate interaction.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

添加到收藏夹

Article Chemistry, Organic

Synthesis and computational analysis of conformationally restricted [3.2.2]- and [3.2.1]-3-azabicyclic diamines

Sreedhar Reddy Tummalapalli, Rohit Bhat, Craig Waitt, Henk Eshuis, David P. Rotella

TETRAHEDRON LETTERS (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Expression, purification, and inhibition profile of dihydrofolate reductase from the filarial nematode Wuchereria bancrofti

Andrew M. Tobias, Dea Toska, Keith Lange, Tyler Eck, Rohit Bhat, Cheryl A. Janson, David P. Rotella, Ueli Gubler, Nina M. Goodey

PLOS ONE (2018)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of a Stress-Activated Protein Kinase Inhibitor for Lymphatic Filariasis

Sreedhar R. Tummalapalli, Rohit Bhat, Agnieszka Chojnowski, Monika Prorok, Tamara Kreissir, Ronald Goldberg, Stacie Canan, Natalie Hawryluk, Deborah Mortensen, Vikram Khetan, Jerome Zeldis, John J. Siekierka, David P. Rotella

ACS MEDICINAL CHEMISTRY LETTERS (2018)

添加到收藏夹

Article Chemistry, Medicinal

Structure activity relationship study of benzo[d]thiazol-2(3H)one based σ receptor ligands

Rohit Bhat, James A. Fishback, Rae R. Matsumoto, Jacques H. Poupaert, Christopher R. McCurdy

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)

添加到收藏夹

Article Chemistry, Medicinal

Structure-activity studies of (-)-epigallocatechin gallate derivatives as HCV entry inhibitors

Rohit Bhat, Amna T. Adam, Jungeun Jasmine Lee, Gaspard Deloison, Yves Rouille, Karin Seron, David P. Rotella

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)

添加到收藏夹

Article Chemistry, Medicinal

Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists

Daniel J. Buzard, Sun Hee Kim, Juerg Lehmann, Sangdon Han, Imelda Calderon, Amy Wong, Andrew Kawasaki, Sanju Narayanan, Rohit Bhat, Tawfik Gharbaoui, Luis Lopez, Dawei Yue, Kevin Whelan, Hussien Al-Shamma, David J. Unett, Hsin-Hui Shu, Shiu-Feng Tung, Steve Chang, Ching-Fen Chuang, Michael Morgan, Abu Sadeque, Zhi-Liang Chu, James N. Leonard, Robert M. Jones

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)

添加到收藏夹

Article Chemistry, Medicinal

Towards the discovery of drug-like epigallocatechin gallate analogs as Hsp90 inhibitors

Rohit Bhat, Amna T. Adam, Jungeun Jasmine Lee, Thomas A. Gasiewicz, Ellen C. Henry, David P. Rotella

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)

添加到收藏夹

Review Chemistry, Medicinal

Early development of sigma-receptor ligands

Sanju Narayanan, Rohit Bhat, Christophe Mesangeau, Jacques H. Poupaert, Christopher R. McCurdy

FUTURE MEDICINAL CHEMISTRY (2011)

添加到收藏夹

Article Chemistry, Analytical

A 96-well filtration method for radioligand binding analysis of σ receptor ligands

James A. Fishback, Abagail Rosen, Rohit Bhat, Christopher R. McCurdy, Rae R. Matsumoto

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2012)

添加到收藏夹

Article Medicine, General & Internal

aDolescent and prEconception health peRspectiVe ofAdultNon-communicable diseases (DERVAN):protocol for rural prospective adolescent girls cohort study in Ratnagiri district of Konkan region of India (DERVAN-1)

Suvarna Patil, Netaji Patil, Charudatta Joglekar, Arvind Yadav, Anup Nilawar, Ulka Banavali, Rohit Bhat, Vijay Dombale, Bhushan Warpe, Rachana Mohite, Kiran Joshi

BMJ OPEN (2020)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.